Dosage of conventional neuroleptic medication and subjective cognitive functioning in schizophrenia

International Clinical Psychopharmacology

Volumn 15, Issue 2, 2000, Pages 77-81

  Krausz, M ^a   Moritz, S ^a   Lambert, M ^a   Naber, D ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cognition; Neuroleptics; Neuropsychology; Self report; Side effects

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; DISEASE DURATION; DOSE CALCULATION; EXTRAPYRAMIDAL SYNDROME; FEMALE; HOSPITAL PATIENT; HUMAN; LANGUAGE ABILITY; MALE; MENTAL DISEASE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; QUESTIONNAIRE; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SELF REPORT;

EID: 0034054407     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200015020-00003     Document Type: Article

References (25)

1. Bilder RM, Lipschutz-Broch L, Reiter G, Geisler SH, Mayerhoff DI, Lieberman JA (1992) Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophr Bull 18:437-448.
2. Brekke JS, Raine A, Ansel M, Lencz T, Bird L (1997) Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia. Schizophr Bull 23:19-28.
3. Cuesta MJ, Peralta V, Juan JA (1996) Abnormal subjective experiences in schizophrenia: its relationships with neuropsychological disturbances and frontal signs. Eur Arch Psychiatry Clin Neurosci 246:101-105.
4. Estes WK, Taylor HA (1964) A detection method and probabilistic models for assessing information processing from brief visual displays. Proc Natl Acad Sci USA 52:446-454.
5. Grace J, Bellus SB, Raulin ML, Herz MI, Priest BL, Brenner V, et al. (1996) Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatr Serv 47:41-45.
6. Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321-330.
7. Green JF, King DJ (1996) Cognitive functioning in schizophrenia. Effects of drug treatment. Drug Ther 6:382-398.
8. Hensel S (1985) Störungen der kognitiven Regulation bei Schizophrenen und Neurotikern: ein Vergleich. Z Klin Psychol 14:331-336.
9. Jahn T, Mussgay L (1989) Die statistische Kontrolle möglicher Medikamenteneinflüsse in experimentalpsychologischen Schizophreniestudien: ein Vorschlag zur Berechnung von Chlorpromazinäquivalenten. Z Klin Psychol 18:257-267.
10. Klosterkötter J, Schultze-Lutter F, Gross G, Huber G, Steinmeyer EM (1997) Early self-experienced neuropsychological deficits and subsequent schizophrenic diseases: an 8-year average follow-up prospective study. Acta Psychiatr Scand 95:396-404.
11. Marder SR (1998) Facilitating compliance with antipsychotic medication. J Clin Psychiatry 59 (Suppl. 3):21-25.
12. Medalia A, Gold J, Merriam A (1988) The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol 3:249-271.
13. Moritz S, Naber D, Krausz M (1998) Neurokognition unter atypischen Neuroleptika - ein Überblick zu Clozapin. Medizin Kunst 10:10-15.
14. Moritz S, Krausz M, Gottwalz E, Lambert M, Naber D (2000) Cognitive dysfunction at baseline predicts symptomatic one-year outcome in first-episode schizophrenics. Psychopathology 33:48-51.
15. Moritz S, Naber D, Krausz M, Lambert M, Andresen B (1999) Neurokognitive Veränderungen in der Behandlung schizophrener Patienten unter Clozapin. In: Clozapin. Pharmakologie und Klinik eines atypischen Neuroleptikums (Naber D, Müller-Spahn F, eds), Berlin: Springer, pp. 90-108.
16. Naber D (1995) A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacology 10 (Suppl. 3):133-138.
17. Nuechterlein KH, Dawson ME (1984) Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull 10:160-203.
18. Overall JE, Gorham DR (1988) The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 24:97-99.
19. Rösler M, Bellaire W, Hengesch G, Kiesling-Muck H, Carls W (1985) Die uncharakteristischen Basissymptome des Frankfurter-Beschwerdefragebogens und ihre Beziehungen zu psychopathologischen Syndromen. Nervenarzt 56:259-264.
20. Rund, BR (1998) A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr Bull 24:425-435.
21. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11-19.
22. Spohn HE, Coyne L, Lacoursiere R, Mazur D, Hayes K (1985) Relation of neuroleptic dose and tardive dyskinesia to attention, information-processing, and psychophysiology in medicated schizophrenics. Arch Gen Psychiatry 42:849-859.
23. Süllwold L (1991) Manual zum Frankfurter Beschwerde-Fragebogen (FBF). Berlin: Springer.
24. WHO (1992) SCAN - Schedules for Clinical Assessment in Neuropsychiatry. World Health Organization, Geneva: Division of Mental Health.
25. Williams RM, Alagaratnam W, Hemsley DR (1984) Relationship between subjective self-report of cognitive dysfunction and objective information-processing performance in a group of hospitalized schizophrenic patients. Eur Arch Psychiatry Neurol Sci 234:48-53.